# Maroun M. Sfeir
**Maroun M. Sfeir** is known for developing the EDTA-modified carbapenem inactivation method (eCIM), a phenotypic test that distinguishes metallo-β-lactamases from serine carbapenemases in drug-resistant bacteria, and for co-developing a CRISPR-based assay for [SARS-CoV-2](https://www.edgepedia.org/sars-cov-2) detection. He published his resistance-diagnostics research from Weill Cornell Medicine and NewYork–Presbyterian Hospital before moving to the University of Connecticut Health Center (UConn Health) in Farmington, Connecticut, where his recent corresponding-author work originates.[1](https://beta.trakmd.com/p/doctor/NDEyMDM/NDE2NjE/ZG9jdG9y/dr-maroun-m-sfeir-farmington-ave-new-britain-ct-dr-maroun-sfeir-video-visits) • [2](https://journals.asm.org/doi/10.1128/jcm.01757-18)
| Key fact | Detail |
|---|---|
| Field | Infectious disease, clinical microbiology, antimicrobial resistance diagnostics[1](https://beta.trakmd.com/p/doctor/NDEyMDM/NDE2NjE/ZG9jdG9y/dr-maroun-m-sfeir-farmington-ave-new-britain-ct-dr-maroun-sfeir-video-visits) |
| Board certifications | [1](https://beta.trakmd.com/p/doctor/NDEyMDM/NDE2NjE/ZG9jdG9y/dr-maroun-m-sfeir-farmington-ave-new-britain-ct-dr-maroun-sfeir-video-visits) |
| Signature work | eCIM for detecting metallo-β-lactamase-producing Enterobacteriaceae, *Journal of Clinical Microbiology*, 2019[2](https://journals.asm.org/doi/10.1128/jcm.01757-18) |
| CRISPR diagnostic | AIOD-CRISPR SARS-CoV-2 assay, ~5-copy detection limit, 20-minute instrument-free visual readout[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC7501862/) |
| Current base | UConn Health, Farmington, Connecticut (Department of Pathology and Laboratory Medicine on recent publications)[4](https://doi.org/10.3390/diagnostics11122287) |
| Society memberships | |
## Education, training and board certification
Sfeir earned his [Doctor of Medicine](https://www.edgepedia.org/doctor-of-medicine) at Lebanese University School of Medicine in Beirut from 2000 to 2007.
## Career and clinical practice
In 2017 he published a Springer book chapter on isolation precautions for visitors to healthcare settings, for which he was corresponding author.[5](https://doi.org/10.1007/978-3-319-60980-5_4) From 2020 onward his corresponding-author papers carry a UConn Health affiliation in Farmington, Connecticut: the 2020 *Clinical Infectious Diseases* paper on imipenem-relebactam susceptibility testing, published 22 June 2020, and, according to the paper itself, the December 2021 review *Diagnosis of Multidrug-Resistant Pathogens of Pneumonia* in *Diagnostics*, whose corresponding author is listed with the Department of Pathology and Laboratory Medicine, University of Connecticut Health Center.[6](https://doi.org/10.1093/cid/ciaa878) • [4](https://doi.org/10.3390/diagnostics11122287)
His ORCID record shows peer-review activity for *Antimicrobial Resistance & Infection Control* (7 reviews) and *BMC Infectious Diseases* (1 review).[7](https://orcid.org/0000-0002-1743-4206)
## Representative work
According to the study "EDTA-Modified Carbapenem Inactivation Method: a Phenotypic Method for Detecting Metallo-β-Lactamase-Producing Enterobacteriaceae," Sfeir was first author of this eCIM study, published in the *Journal of Clinical Microbiology* on 26 April 2019 (vol. 57, no. 5, e01757-18), from the Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine. [EDTA-Modified Carbapenem Inactivation Method: a Phenotypic Method for Detecting Metallo-β-Lactamase-Producing Enterobacteriaceae](https://doi.org/10.1128/jcm.01757-18) described and evaluated the assay and reported its adoption by a standards body.[2](https://journals.asm.org/doi/10.1128/jcm.01757-18)
## The EDTA-modified carbapenem inactivation method
Carbapenemase-producing [Enterobacteriaceae](https://www.edgepedia.org/enterobacteriaceae) are a global health concern, and rapid, accurate detection in any clinical microbiology laboratory, including resource-limited settings, is essential to contain their spread.[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC6498035/) The modified carbapenem inactivation method (mCIM) detects carbapenemase activity with high sensitivity and specificity, but it cannot distinguish serine carbapenemases (class A and D enzymes) from metal-dependent metallo-β-lactamases (MBLs). That distinction matters for epidemiologic, infection control, and therapeutic purposes, because the enzyme class determines which drugs may still work and how an outbreak is tracked.[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC6498035/)
The eCIM answers this by adding EDTA; used together with the mCIM, it discriminates between serine and metal-dependent carbapenemases. In the development study the eCIM had an overall sensitivity and specificity of 100% and was adopted by a standards body.[2](https://journals.asm.org/doi/10.1128/jcm.01757-18)
Independent evaluations returned more varied results. A 2020 evaluation of 195 carbapenem-resistant Enterobacteriaceae isolates found the mCIM alone at 100% sensitivity and 100% specificity, against 84.8% sensitivity and 97.8% specificity for the older modified Hodge test; the mCIM/eCIM combination detected metallo-carbapenemases with 89.3% sensitivity and 98.7% specificity against genotypic PCR, with three MBL-producing isolates escaping eCIM detection.[9](https://link.springer.com/article/10.1186/s12866-020-02010-3) A 2020 follow-up applying the method to metallo-β-lactamase-harboring *Pseudomonas aeruginosa* found high eCIM sensitivity for NDM and VIM carbapenemases but not for IMP-type enzymes, extending the method beyond Enterobacteriaceae while exposing that limitation.[10](https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-020-01902-8)
## CRISPR-based SARS-CoV-2 diagnostics
In 2020 Sfeir co-authored the All-In-One Dual CRISPR-Cas12a (AIOD-CRISPR) assay for one-pot, ultrasensitive, and visual SARS-CoV-2 detection, according to the paper "Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay". The reverse-transcriptase version targets the SARS-CoV-2 nucleoprotein gene with two CRISPR RNAs and consistently detected down to about 5 copies of SARS-CoV-2 N RNA targets in both real-time and visual detection modes.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC7501862/) The assay was validated on COVID-19 clinical swab samples with results consistent with RT-PCR. For point-of-care use, a low-cost [hand warmer](https://www.edgepedia.org/hand-warmer) (about $0.3) served as the incubator, enabling instrument-free visual detection within 20 minutes, without the thermocyclers or fluorescent readers conventional PCR requires.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC7501862/)
## His methods in the wider diagnostic landscape
Phenotypic carbapenemase tests compete with molecular panels on speed and with each other on accuracy. In a 2023 study of 195 *Klebsiella pneumoniae* isolates (150 carbapenem-resistant), CarbaNP, mCIM, and eCIM showed 96.0%, 95.4%, and 96.7% sensitivity respectively for detecting carbapenem-resistant *K. pneumoniae*, with all three methods at 100% specificity.[11](https://doi.org/10.1089/mdr.2023.0040) A retrospective comparison of six methods on 88 [CRKP](https://www.edgepedia.org/carbapenem-resistant-klebsiella-pneumoniae) strains from a 2016–2023 collection, using PCR sequencing as the reference, reported mCIM at 94.12% sensitivity and 100% specificity but eCIM at only 67.06% sensitivity and 66.67% specificity, while GeneXpert Carba-R reached 97.65% sensitivity and 100% specificity with a 48-minute report time against 22–28 hours for mCIM/eCIM.[12](https://brieflands.com/journals/jjm/articles/153574) On the viral side, the multiplexed CRISPR-microfluidic mCARMEN platform tests for up to 21 respiratory viruses including SARS-CoV-2 and identified 6 SARS-CoV-2 variant lineages including Delta and Omicron with near-perfect concordance to sequencing-based classification across 2,088 patient specimens, showing where CRISPR diagnostics scale beyond single-target assays.[13](https://www.nature.com/articles/s41591-022-01734-1)
## References
1. Dr. Maroun M Sfeir, MD, trakMD profile. https://beta.trakmd.com/p/doctor/NDEyMDM/NDE2NjE/ZG9jdG9y/dr-maroun-m-sfeir-farmington-ave-new-britain-ct-dr-maroun-sfeir-video-visits
2. EDTA-Modified Carbapenem Inactivation Method: a Phenotypic Method for Detecting Metallo-β-Lactamase-Producing Enterobacteriaceae. Journal of Clinical Microbiology. https://journals.asm.org/doi/10.1128/jcm.01757-18
3. Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay. https://pmc.ncbi.nlm.nih.gov/articles/PMC7501862/
4. Sfeir, M.M. Diagnosis of Multidrug-Resistant Pathogens of Pneumonia. Diagnostics 2021, 11, 2287. https://doi.org/10.3390/diagnostics11122287
5. Isolation Precautions for Visitors to Healthcare Settings (Springer book chapter). https://doi.org/10.1007/978-3-319-60980-5_4
6. Imipenem-relebactam for Treatment of Carbapenem-resistant Gram-negative Bacteria: Where Do We Stand on In Vitro Susceptibility Testing? Clinical Infectious Diseases, 2020. https://doi.org/10.1093/cid/ciaa878
7. Maroun Sfeir (0000-0002-1743-4206), ORCID. https://orcid.org/0000-0002-1743-4206
8. EDTA-Modified Carbapenem Inactivation Method (PubMed Central full text). https://pmc.ncbi.nlm.nih.gov/articles/PMC6498035/
9. Combination of mCIM and eCIM for phenotypic detection of carbapenemase-producing Enterobacteriaceae. BMC Microbiology, 2020. https://link.springer.com/article/10.1186/s12866-020-02010-3
10. EDTA-modified carbapenem inactivation method (eCIM) for detecting IMP metallo-β-lactamase-producing Pseudomonas aeruginosa. BMC Microbiology, 2020. https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-020-01902-8
11. Performance of CarbaNP, mCIM, and eCIM Methods for Detecting Carbapenem-Resistant Klebsiella pneumoniae Isolates. https://doi.org/10.1089/mdr.2023.0040
12. Methodology Comparison of Multiple Phenotypic and Genotypic Tests in Carbapenem-Resistant Klebsiella pneumoniae. https://brieflands.com/journals/jjm/articles/153574
13. Multiplexed CRISPR-based microfluidic platform (mCARMEN) for clinical testing of respiratory viruses. Nature Medicine. https://www.nature.com/articles/s41591-022-01734-1
---
*Topic: Encyclopedia › Life and health › Life and health scientists › Medical and health researchers › Researchers in infectious disease, epidemiology, vaccines, and global health › Antimicrobial resistance and antimicrobial stewardship*
*Initially written Sep 21, 2026 · Reviewed: Sep 25, 2026 · Edited: Sep 25, 2026; Oct 11, 2026; Oct 15, 2026; Oct 21, 2026 · Last review: Sep 25, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license